Wall Street Associates’s Adamas Pharmaceuticals ADMS Stock Holding History

Wall Street Associates’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$323K	Sell	19,100 -125,000	-87%	-$1.93M	0.21%	165
2016 Q3	$2.37M	Buy	144,100 +19,100	+15%	+$290K	0.81%	50
2016 Q2	$1.89M	Hold	125,000	–	–	0.76%	48
2016 Q1	$1.81M	Hold	125,000	–	–	0.75%	50
2015 Q4	$3.54M	Sell	125,000 -100,000	-44%	-$1.68M	1%	13
2015 Q3	$3.77M	Hold	225,000	–	–	0.72%	43
2015 Q2	$5.9M	Hold	225,000	–	–	0.56%	65
2015 Q1	$3.94M	Hold	225,000	–	–	0.37%	94
2014 Q4	$3.91M	Hold	225,000	–	–	0.37%	92
2014 Q3	$4.19M	Hold	225,000	–	–	0.43%	87
2014 Q2	$4.11M	Buy	+225,000	New	+$4.03M	0.35%	105

Other funds holding ADMS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wall Street Associates's ADMS Position: Q4 2016 in Review

Wall Street Associates reduced its Adamas Pharmaceuticals (ADMS) stake by 87% in Q4 2016, selling an estimated $1.93M and leaving 19,100 shares worth $323K. The position accounts for 0.21% of the portfolio, ranked #165.

Wall Street Associates first reported a position in ADMS in Q2 2014 and has held it in 11 quarters since. The position peaked at $5.9M in Q2 2015. 78 funds tracked by Wall St. Rank hold ADMS as of Q4 2016.

Wall Street Associates held 19,100 shares of Adamas Pharmaceuticals worth $323K as of Q4 2016.
Wall Street Associates sold 125,000 Adamas Pharmaceuticals shares in Q4 2016, an estimated $1.93M.
Adamas Pharmaceuticals made up 0.21% of Wall Street Associates's portfolio in Q4 2016, its #165 holding.
Wall Street Associates first reported a position in Adamas Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
Wall Street Associates's Adamas Pharmaceuticals position peaked at $5.9M in Q2 2015.
78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.